The better choice depends on your budget, response to medication, side effect profile, and weight loss goals
In addition to aforementioned properties of GLP-1 agonists, it can also reduce hypertension by activating and phosphorylating endothelial nitric oxide synthase pathways, thus increasing the bioavailability of nitric oxide which promotes vasodilation
Potential side effects observed during clinical research include mild nausea, vomiting, diarrhea, and constipation
This is not a 12-week cycle
Pretty much what I said, guess were going to have to wait for more data on whether this issue is actually an issue
In theory, SGLT-2 inhibitors should be considered before GLP-1RA because of the reduction in both CV and total deaths associated with their use